The U.S. Food and Drug Administration has approved Incyte's eczema treatment for children aged between 2 and 11 years, the ...

The U.S. Food and Drug Administration has approved Incyte's eczema cream for children aged between 2 and 11 years, the ...

LEO Pharma Presents Late-Breaking Phase 3 Delgocitinib Cream Data in Adolescents with Moderate to Severe Chronic Hand Eczema ...

Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis ...

US drug developer Nektar Therapeutics saw its shares rise 9% to $55.66 following release of new data from the ongoing REZOLVE ...

A new international study presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2025 reveals ...

Incyte (INCY) “announced that the FDA has approved Opzelura cream 1.5%, a topical Janus kinase inhibitor, for the short-term and non-continuous ...

Adults with atopic dermatitis, whether diagnosed during childhood or adulthood, experienced higher rates of suicidal thoughts ...

Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) stock jumped 7% Thursday after the company announced positive results from its REZOLVE-AD Phase 2b study of rezpegaldesleukin for moderate-to-severe ...

Rosacea can cause redness, breakouts, and discomfort. Here, dermatologists share moisturizers that may help color-correct ...

Eczema can be a challenging condition, but with the right awareness, early recognition, and consistent care, parents can make a significant difference in their baby’s skin health ...

Don’t miss this chance to win a bundle of three best-selling heroes from Dermatology M, the face and bodycare brand that ...